SCHEMBL10271389

SCHEMBL10271389

CCc1nc2ccc(OC(F)(F)F)cc2s1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.62
RAB9A P51151 4/20 0.62
CYP3A4 P08684 3/20 0.62
GAA P10253 2/20 0.62
SCN4A P35499 2/20 0.62
SCN9A Q15858 2/20 0.62
TP53 P04637 2/20 0.62
HSD17B10 Q99714 2/20 0.62
CYP1A2 P05177 2/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
GMNN O75496 1/20 0.62
USP2 O75604 1/20 0.62
LMNA P02545 1/20 0.62
ADORA3 P0DMS8 1/20 0.62
CYP2C9 P11712 1/20 0.62
PKM P14618 1/20 0.62
ALOX15 P16050 1/20 0.62
NFKB1 P19838 1/20 0.62
SLC6A2 P23975 1/20 0.62
BLM P54132 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12468602 0.85 CYP3A4 (0.62) NPC1RAB9ACYP3A4GAASCN4A
SCHEMBL12963734 0.82 NPC1 (0.53) NPC1RAB9ACYP3A4GAASCN4A
SCHEMBL5351987 0.81 CYP1A2 (0.61) NPC1RAB9ACYP3A4GAACYP1A2
SCHEMBL10271734 0.80 KMT2A (0.68) NPC1RAB9ACYP3A4GAATP53
SCHEMBL2665688 0.80 NPC1 (0.68) NPC1RAB9ACYP3A4GAASCN4A
SCHEMBL15063747 0.79 NPC1 (0.52) NPC1RAB9ACYP3A4GAASCN4A
SCHEMBL29699053 0.79 DYRK1A (0.53) NPC1RAB9ACYP3A4GAASCN4A
SCHEMBL9776965 0.79 DYRK1A (0.65) NPC1RAB9ACYP3A4GAASCN4A
SCHEMBL12963894 0.79 CYP3A4 (0.58) NPC1RAB9ACYP3A4GAASCN4A
SCHEMBL3091070 0.78 NPC1 (0.69) NPC1RAB9ACYP3A4GAASCN4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107007598-A 2‑(N ethyls)6 trifluoromethoxy benzo thiazoles as cancer therapy drug application 西北工业大学 2017-08-04 CN disclosed
US-20120035178-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands BRISTOL-MYERS SQUIBB COMPANY 2012-02-09 US disclosed
US-20120035189-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands BRISTOL-MYERS SQUIBB COMPANY 2012-02-09 US disclosed
US-7863291-B2 Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands BRISTOL-MYERS SQUIBB COMPANY (US) 2011-01-04 US disclosed
US-20090270405-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS BRISTOL-MYERS SQUIBB COMPANY 2009-10-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035189-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands CHRNA7, CHRNA5, CHRNA6 NPC1 896/4885RAB9A 333/4885CYP3A4 2815/4885
US-20120035178-A1 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands CHRNA7, CHRNA5, CHRNA6 NPC1 896/4885RAB9A 333/4885CYP3A4 2815/4885
US-20090270405-A1 QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS CHRNA7, CHRNA5, CHRNA6 NPC1 896/4885RAB9A 333/4885CYP3A4 2815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.